Search Results



Your search for Pasi A. Jänne, MD, PhD matches 15 pages

Showing 1 - 15


Pasi A. Jänne, MD, PhD, Receives ESMO Translational Research Award

THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has chosen Pasi A. Jänne, MD, PhD, to receive the ESMO Translational Research Award for his research contributions in lung cancer. Dr. Jänne is Director of the Lowe Center for Thoracic Oncology and Director of the Belfer Center for Applied Cancer...

AACR Honors Recipients of 2018 Scientific Achievement Awards and Lectureships

THE AMERICAN ASSOCIATION for Cancer Research (AACR) honors the following cancer researchers and clinicians who were recognized for their scientific achievements during the AACR Annual Meeting 2018:   Isaiah J. Fidler, DVM, PhD, FAACR, AACR President (1984-1985), Fellow of the AACR Academy and...

Alice T. Shaw, MD, PhD, and Pasi A. Jänne, MD, PhD, Named Co‑Leaders of SU2C-ACS Dream Team on Lung Cancer

Alice T. Shaw, MD, PhD, of Massachusetts General Hospital Cancer Center, and Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, have been named co-leaders of the Stand Up to Cancer (SU2C)-American Cancer Society (ACS) Lung Cancer Dream Team, joining co-leader Jedd Wolchok, MD, PhD, of...

issues in oncology
lung cancer
gastrointestinal cancer
prostate cancer
colorectal cancer

At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints

The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...

ASCO President-Elect Bruce E. Johnson, MD, FASCO, Reflects on Volunteer Service, Plans for Presidential Term

Bruce E. Johnson, MD, FASCO, began his term as ASCO President-Elect in June 2016 and will serve as 2017–2018 President. A thoracic cancer specialist, Dr. Johnson is Chief Clinical Research Officer and institute physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical...

lung cancer

Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).

lung cancer

Selumetinib/Docetaxel Shows Promising Activity in Previously Treated KRAS-mutant Non-Small Cell Lung Cancer

Currently, there are no approved therapies for KRAS-mutant non–small cell lung cancer (NSCLC), and few clinical trials have been performed specifically in this setting. In a recent article in Lancet Oncology, Pasi A. Jänne, MD, PhD, Scientific Director, Belfer Institute for Applied Cancer Science,...

lung cancer

Role of Erlotinib in EGFR Wild-Type Lung Cancer 

I welcomed Matthew Stenger’s Journal Spotlight on the TAILOR trial in the August 15 issue of The ASCO Post (“Docetaxel Superior to Erlotinib in Second-Line Treatment of Advanced Non–Small Cell Lung Cancer With Wild-Type EGFR”). The trial was recently published online in Lancet Oncology,1 and...

lung cancer

Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer

Preliminary evidence suggests that AZD9291, a novel mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, may become a treatment option for patients with advanced, EGFR-mutant, non–small cell lung cancer (NSCLC) that has progressed on standard EGFR inhibitors....

integrative oncology

Getting Results: How Oncologists and Pathologists Can Work Together to Facilitate Molecular Testing

Advances in molecular testing mean that highly specific information can be detailed about the molecular characteristics of a patient’s tumor, as well as indications of potential responsiveness to targeted therapy. But getting those detailed results from the pathologists can be a challenge to many...

lung cancer

NIH Announces Launch of Precision Medicine Trials in Early-Stage Lung Cancer

The National Institutes of Health (NIH) recently announced the launch of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials, or ALCHEMIST. The purpose of the trial, which has three components, is to identify patients with early-stage lung cancer whose tumors harbor...

issues in oncology
lung cancer

The Basket Trial: An Evolving Clinical Trial Design

The recently published results of the CUSTOM (Molecular Profiling and Targeted Therapies in Advanced Thoracic Malignancies) trial, reviewed in this issue of The ASCO Post, describe a basket trial focused on identifying molecular biomarkers in advanced non­­–small cell lung cancer (NSCLC), small...

lung cancer

Outcomes of the CUSTOM ‘Basket’ Trial of Molecular Profiling and Targeted Therapy in Advanced Thoracic Malignancies

In the phase II CUSTOM trial reported in the Journal of Clinical Oncology, Ariel Lopez-Chavez, MD, Anish Thomas, MD, and colleagues performed molecular profiling of tumors in patients with advanced non–small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or thymic malignancies and...

lung cancer

‘Encouraging Results’ With Newer EGFR TKIs in Patients With NSCLC Who Progressed After Prior EGFR TKI Therapy

Two studies of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among patients with non–small cell lung cancer (NSCLC) who had progressive disease following treatment with a first-generation EGFR tyrosine kinase inhibitor “show encouraging results,” according to...

lung cancer

AZD9291 Updates Encouraging for Treatment-Resistant NSCLC

At the 16th World Conference on Lung Cancer, several studies showed consistent activity with the investigational third-generation inhibitor AZD9291 in patients with advanced non–small cell lung cancer (NSCLC) that is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors....

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.